<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The delivery of proteins across the blood-brain barrier is severely limited by the proteins' size and biochemical properties </plain></SENT>
<SENT sid="1" pm="."><plain>Eleven-amino acid human <z:hpo ids='HP_0002721'>immunodeficiency</z:hpo> virus TAT protein is able to cross cell membranes even when coupled with larger <z:chebi fb="7" ids="16670">peptides</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>We evaluated whether TAT-Bcl-X(L) fusion protein is protective in focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Mice underwent 30 or 90 minutes of intraluminal middle cerebral artery thread occlusion </plain></SENT>
<SENT sid="4" pm="."><plain>TAT-Bcl-X(L), TAT-beta-galactosidase, or TAT-GFP (0.6 nmol each) were applied intravenously over 10 minutes either 1 hour before or immediately after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Additional animals received no TAT protein infusions </plain></SENT>
<SENT sid="6" pm="."><plain>We show that the brain tissue is progressively transduced with TAT proteins within 3 to 4 hours after intravenous delivery </plain></SENT>
<SENT sid="7" pm="."><plain>We provide evidence that TAT-Bcl-X(L) treatment reduces <z:mpath ids='MPATH_124'>infarct</z:mpath> volume and neurological deficits after long ischemic insults lasting 90 minutes, when applied both before and after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>After short insults, lasting only 30 minutes, TAT-Bcl-X(L) further diminishes the number of caspase-3-reactive and DNA fragmented cells and increases the number of viable neurons in the striatum </plain></SENT>
<SENT sid="9" pm="."><plain>Our results indicate that TAT fusion proteins are elegant and powerful tools that might be of clinical interest for <z:hpo ids='HP_0001297'>stroke</z:hpo> treatment, because factors may be intravenously applied </plain></SENT>
<SENT sid="10" pm="."><plain>Thus, fusion proteins may open fascinating perspectives for future research </plain></SENT>
</text></document>